Medicare speeds payment for unproven devices, betting on innovation.

What it does

This bill allows Medicare to pay hospitals extra money for using newly approved medical devices that the FDA has designated as 'breakthrough' innovations, even before those devices complete full FDA approval—as long as they receive some form of FDA clearance by July 1 of the fiscal year in question. The goal is to speed patient access to promising new medical technologies without waiting for the full approval process to finish.

Why we flagged it

The bill's operative mechanism is a conditional payment pathway for breakthrough devices under Medicare's New Technology Add-On Payment program. It is not a blanket deregulation but a targeted reimbursement rule change designed to incentivize adoption of FDA-designated innovations before full approval.

What the text implies

• Hospitals gain financial incentive to adopt devices with incomplete safety/efficacy data; the 'breakthrough' designation is an FDA expedited-review marker, not a completed safety finding.
• Budget-neutral language in clause (III) may be aspirational rather than binding; if devices are widely adopted, actual costs could exceed projections, pressuring Medicare finances.
• Retroactive effective date (July 1, 2023) means devices approved after that date become immediately eligible upon enactment, potentially creating a windfall for early adopters.
• No explicit requirement for post-market surveillance or outcome reporting; Medicare pays without mandatory data collection on whether conditional approvals improve patient outcomes.
• Device manufacturers gain a faster path to reimbursement and market adoption, reducing time-to-revenue for breakthrough devices relative to traditional approval timelines.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Medicare beneficiaries gain faster access to potentially beneficial new medical technologies, which is a concrete public health benefit. However, the bill creates a financial incentive for hospitals to adopt devices before full safety and efficacy data are available, and it requires Medicare to pay extra without budget offset—shifting costs to the program and potentially to beneficiaries through higher premiums or reduced coverage elsewhere.

Who stands to gain

• medical device manufacturers (breakthrough device makers)
• hospitals and health systems (add-on payment revenue)
• device distributors and suppliers

Named in the bill

Medicare, FDA (Food and Drug Administration), Section 1886(d)(5)(K) of Social Security Act, Section 510(k), 513(f)(2), 515 of Federal Food, Drug, and Cosmetic Act, Section 515B of Federal Food, Drug, and Cosmetic Act, 42 CFR 412.87(f)(2), New Technology Add-On Payment (NTAP) Program, breakthrough device designation

Where it stands

2 cosponsors: 2 Democrats.

• Jul 16, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jul 16, 2025 — Referred to House Committee on Energy and Commerce and House Committee on Ways and Means · Congress.gov: “Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 3 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,180,000 in lobbying spend. A filing names 2 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Mike Carey, the sponsor, reported $1,809,017 in PAC receipts in the 2026 cycle.

• Vantive Us Healthcare LLC — $1,120,000 on 2 filings
• Vantive Us Healthcare LLC — $60,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.